Comparison of Model-Based Tests and Selection Strategies to Detect Genetic Polymorphisms Influencing Pharmacokinetic Parameters
- 7 November 2008
- journal article
- research article
- Published by Taylor & Francis in Journal of Biopharmaceutical Statistics
- Vol. 18 (6) , 1084-1102
- https://doi.org/10.1080/10543400802369012
Abstract
We evaluate by simulation three model-based methods to test the influence of a single nucleotide polymorphism on a pharmacokinetic parameter of a drug: analysis of variance (ANOVA) on the empirical Bayes estimates of the individual parameters, likelihood ratio test between models with and without genetic covariate, and Wald tests on the parameters of the model with covariate. Analyses are performed using the FO and FOCE method implemented in the NONMEM software. We compare several approaches for model selection based on tests and global criteria. We illustrate the results with pharmacokinetic data on indinavir from HIV-positive patients included in COPHAR 2-ANRS 111 to study the gene effect prospectively. Only the tests based on the EBE obtain an empirical type I error close to the expected 5%. The approximation made with the FO algorithm results in a significant inflation of the type I error of the LRT and Wald tests.Keywords
This publication has 35 references indexed in Scilit:
- The SAEM algorithm for group comparison tests in longitudinal data analysis based on non‐linear mixed‐effects modelStatistics in Medicine, 2007
- Design in nonlinear mixed effects models: Optimization using the Fedorov–Wynn algorithm and power of the Wald test for binary covariatesStatistics in Medicine, 2007
- Modelling the influence of MDR1 polymorphism on digoxin pharmacokinetic parametersEuropean Journal of Clinical Pharmacology, 2007
- Association ofCYP2C8, CYP3A4, CYP3A5, andABCB1Polymorphisms with the Pharmacokinetics of PaclitaxelClinical Cancer Research, 2005
- Evaluation by simulation of tests based on non‐linear mixed‐effects models in pharmacokinetic interaction and bioequivalence cross‐over trialsStatistics in Medicine, 2005
- Characterization of the humanMDR1 geneThe AAPS Journal, 2005
- High Variability of Indinavir and Nelfinavir Pharmacokinetics in HIV-Infected Patients with a Sustained Virological Response on Highly Active Antiretroviral TherapyClinical Pharmacokinetics, 2005
- Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first‐pass metabolism, CYP2D6 genotype and formulation‐dependent bioavailabilityBritish Journal of Clinical Pharmacology, 2003
- Estimating the Dimension of a ModelThe Annals of Statistics, 1978
- A new look at the statistical model identificationIEEE Transactions on Automatic Control, 1974